In the subgroup with the higher half of CD56+ cells infiltrating in tumor stroma, relapse was observed in 8 patients of the vitamin D group (7.4%), which was significantly lower than in the placebo group (16 patients, 20.5%) (SHR, 0.35; 95%CI, 0.15–0.82) (Figure 3A), but equivalent (vitamin D, 28 patients (25.2%) vs. placebo, 17 (22.7%)) in the subgroup with the lower half (SHR, 1.21; 95%CI, 0.68–2.19) (Figure 3B). The gene discussed is NCAM1; the disease is neoplasm.